We are driven by the passion to nurture and preserve the precious moments of everyday life for all people, regardless of their health condition. From treatment to disease prevention, we will continue to develop innovative new drugs that contribute to better health and bring smiles to the faces of people everywhere.
Latest News
-
April 28, 2026
News Releases
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
-
April 28, 2026
News Releases
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development
-
April 21, 2026
News Releases
Update on the Phase 3 STAR-121 Study of Anti-TIGIT Antibody Domvanalimab and Anti-PD-1 Antibody Zimberelimab in Non-Small Cell Lung Cancer
-
March 10, 2026
News Releases
Taiho Pharmaceutical Announces Personnel Changes
-
January 14, 2026
News Releases
Otsuka Holdings Submits Commitment Letter to Obtain Science-Based Targets Validation for the Entire Otsuka Group
-
April 28, 2026
Information
Otsuka Holdings announces FY2026 1Q financial results
-
April 15, 2026
Information
Taiho Ventures, LLC Celebrates 10th Anniversary
-
June 07, 2024
Information
Otsuka Holdings announces Fourth Medium-Term Management Plan(2024-2028)
-
January 09, 2024
Information
Donations to Support Relief Efforts Following the Noto Peninsula Earthquake
-
February 22, 2023
Information
Donations to Support Relief Efforts Following Earthquakes in Turkey and Syria
-
March 17, 2022
Information
■Otsuka Holdings Donations for Humanitarian Support to Ukrainian People
-
July 12, 2018
Information
Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）
MOVIE
TAIHO PHARMA STORY
Introducing Taiho Pharmaceutical’s history and its unique approaches in R&D.
This video is not intended to constitute promotion or advertisement of any products.